SciBX: Science-Business eXchange
As published Thursday, October 23, 2014
By Lauren Martz, Staff Writer
It might be a day late and a dollar short, but the U.S.
government is finally getting around to addressing what many experts think is
the big unserved need in antibiotic resistance-new diagnostics. Faster, more
sensitive and versatile diagnostic technologies that can keep up with the
emergence of resistant strains are needed both for improving treatment and
optimizing clinical trials.
Changes in circulating levels of branched-chain amino acids detectable 2-5 years before the onset of pancreatic cancer could lead to diagnostic markers for the indication.
CRISPR-based antimicrobials can resensitize antibiotic-resistant bacteria by targeting specific resistance genes and could add new tools for combating resistance.